Apple
- Generic Name
- Apple
- Drug Type
- Biotech
- Unique Ingredient Identifier
- B423VGH5S9
- Background
Apple allergenic extract is used in allergenic testing.
Persist AI Raises $12M Series A, Launches Cloud Lab to Revolutionize Pharmaceutical Formulation Development
• Persist AI has secured $12 million in Series A funding to expand its AI-driven robotics platform that reduces drug formulation development time from years to months.
• The company's Cloud Lab platform enables pharmaceutical companies to remotely develop formulations using robotic laboratory facilities, testing 700 formulations in two months compared to the industry standard of 10-15 per month.
• Persist AI's technology miniaturizes testing processes, requiring just 1 mL of liquid and a few milligrams of material compared to traditional methods that need 1000 mL and several grams.
Roche and Regeneron Announce Multi-Billion Dollar Investments in US Manufacturing Amid Tariff Concerns
• Roche has committed $50 billion to expand its US operations over five years, including new manufacturing facilities and R&D centers, with plans to create over 12,000 new jobs nationwide.
• Regeneron is investing more than $3 billion in US operations through a partnership with Fujifilm Diosynth Biotechnologies, nearly doubling its large-scale manufacturing capacity in the country.
• These pharmaceutical investments come as President Trump continues to threaten sector-specific tariffs, with Roche stating it will eventually export more medicines from the US than it imports.
Northwestern Medicine Launches Landmark Study Using Apple Watch to Revolutionize AFib Treatment
• Northwestern Medicine researchers are initiating a seven-year clinical trial to determine if wearable technology can reduce continuous blood thinner use in atrial fibrillation patients, potentially decreasing bleeding risks and improving quality of life.
• The REACT-AF trial will monitor participants using Apple Watch technology, implementing a "pill-in-pocket" approach where patients take anticoagulants only during detected AFib episodes rather than daily for life.
• With AFib affecting over 5 million Americans and expected to reach 12.1 million by 2030, this NIH-funded study could fundamentally change treatment standards by personalizing anticoagulation therapy based on real-time heart rhythm monitoring.
EvolutionaryScale Launches with $142M to Transform Drug Discovery Using Advanced AI Protein Platform
• Former Meta researchers have launched EvolutionaryScale with $142 million in seed funding, backed by prominent tech investors and industry giants NVIDIA and Amazon.
• The company's ESM3 platform, trained on 4 billion proteins, can generate novel protein structures that would naturally take millions of years to evolve, demonstrating breakthrough capabilities in protein engineering.
• EvolutionaryScale plans to partner with pharmaceutical companies while offering free academic access through NVIDIA's BioNeMo platform, positioning itself as a major player in AI-driven drug discovery.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath